Company intelligence / Profile preview

Remilk

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Remilk has developed and commercialized a proprietary precision fermentation process that enables large-scale production of animal-free milk proteins. Their products are free from lactose, cholesterol, hormones, and antibiotics. The company has received regulatory approvals including self-GRAS status in the US and Health Canada’s “Letter of No Objection,” making it the first to receive such approval for non-animal dairy protein in Canada. Plans for large-scale manufacturing facilities have been announced but some have been postponed.

Modalities: Recombinant protein
Industry: Non-Drug Biotech

Drug pipeline

1 asset

r-βLG

Commercial

Indications: Lactose intolerance

Partnerships

EuropaBio membership (industry association)Collaborations with global food manufacturers (specific partners not disclosed)

Beyond the preview

Go deeper on Remilk.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remilk.

Explore the full profile